Alembic Pharmaceuticals Limited has informed the Exchange about Credit Rating
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received a credit rating reaffirmation from CARE Ratings on its Commercial Paper (CP) program. The rating has been kept at CARE A1+, which is the highest short-term rating, indicating the strongest capacity to meet short-term financial obligations. Importantly, the total CP limit has been enhanced from Rs. 750 crore to Rs. 1,100 crore, giving the company greater access to short-term funding. The review by CARE considered the company's audited financial performance for FY25. Commercial Papers are short-term debt instruments used by companies to raise money for working capital and other short-term needs.
This is a positive development for shareholders — the highest possible short-term rating being maintained, combined with a 47% increase in the CP limit, signals strong financial health and improved access to short-term borrowings at favourable rates.